A commercial partnership with Gilead Sciences for filgotinib (Jyseleca), a treatment for rheumatoid arthritis, in Japan, South Korea, Taiwan, Hong Kong and Singapore. This is a regional commercial partnership for a single product, including an upfront payment and development and sales milestones.